Patents Assigned to SYGNIS Bioscience GmbH & Co. KG
  • Methods of treating neurological conditions with hematopoietic growth factors
    Patent number: 7695723
    Abstract: The present invention relates to a method of treating a neurological condition in a mammal by administering at least one hematopoietic growth factor.
    Type: Grant
    Filed: June 30, 2004
    Date of Patent: April 13, 2010
    Assignee: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Wolf-Ruediger Schaebitz, Armin Schneider, Carola Krueger, Clemens Sommer, Stefan Schwab, Rainer Kollmar, Martin Maurer, Daniela Weber, Nikolaus Gassler
  • SCREENING METHOD TO IDENTIFY PROTECTIVE SUBSTANCES FOR THE TREATMENT OF NEURODEGENERATIVE AND/OR ISCHAEMIC DISEASES
    Publication number: 20090305289
    Abstract: The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.
    Type: Application
    Filed: July 7, 2009
    Publication date: December 10, 2009
    Applicant: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Martin Maurer, Wolfgang Kuschinsky, Armin Schneider, Alfred Bach
  • Screening method for identifying protective substances for treating neurodegenerative and/or ischemic disorders
    Patent number: 7575857
    Abstract: The present invention relates to a screening method for the identification of protective substances which influence haemoglobin formation in neuronal, myocardial and/or skeletomuscular cells, as well as to recombinant constructs, host cells and transgenic animals for the implementation of this method. In addition, the present invention relates to a diagnostic method for the differential diagnosis of neurodegenerative and/or ischaemic diseases in mammals and the use of haemoglobin, a globin or a mutein or fusion protein thereof or a corresponding nucleic acid for the treatment of neurodegenerative and/or ischaemic diseases in mammals. The invention furthermore relates to constructs for gene therapy of such diseases.
    Type: Grant
    Filed: March 14, 2003
    Date of Patent: August 18, 2009
    Assignee: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Martin Maurer, Wolfgang Kuschinsky, Armin Schneider, Alfred Bach
  • Nucleic acid molecule encoding a neuronal serine-threonine protein kinase
    Patent number: 7361502
    Abstract: The present invention relates to a gene and the coded protein thereof that is involved in the development of sequelae of local ischaemia. The new protein is a serine threonine protein kinase and provides a new therapeutic approach to the prophylaxis and therapy of apoplexy.
    Type: Grant
    Filed: May 17, 2001
    Date of Patent: April 22, 2008
    Assignee: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Armin Schneider, Bettina Klaussner, Achim Fischer, Dieter Newrzella, Bernhard Götz, Moritz Rossner, Gisela Eisenhardt, Rohini Kuner, Annette Trutzel, Birgitta Kammandel, Stephanie Jomana Naim, Markus Schwaninger
  • Method of treating amytrophic lateral sclerosis using melatonin
    Patent number: 7361681
    Abstract: The present invention relates to the treatment of amyotrophic lateral sclerosis (ALS) and/or the improvement of motor function in individuals in need of such improvement using a melatonin compound or a pharmaceutical salt of the melatonin compound.
    Type: Grant
    Filed: March 28, 2003
    Date of Patent: April 22, 2008
    Assignee: SYGNIS Bioscience GmbH & Co. KG
    Inventors: Hannelore Ehrenreich, Ruediger Hardeland, Klaus-Armin Nave, Jochen Weishaupt